Literature DB >> 3411374

Kinetic analysis of technetium-99m d,1-HM-PAO decomposition in aqueous media.

J C Hung1, M Corlija, W A Volkert, R A Holmes.   

Abstract

Technetium-99m-d,1-hexamethylpropyleneamine oxime [99mTc]d,1-HM-PAO) is a neutral-lipophilic chelate formed from a kit in high yield by stannous reduction of Na99mTcO4-. Of three methods used to analyze the purity of the 99mTc complexes, a single strip method using ether as the developing solvent was the most rapid and simple to perform. The lipophilic chelate converts to 99mTcO4- and other hydrophilic products with time and this limits the useful lifetime of the preparations. The rate of decomposition of [99mTc]d,1-HM-PAO increased in the presence of excess stannous ion and at pH greater than 9.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3411374

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  9 in total

1.  Motor stimulation response by technetium-99m hexamethylpropylene amine oxime split-dose method and single photon emission tomography.

Authors:  P Pantano; V Di Piero; M Ricci; C Fieschi; L Bozzao; G L Lenzi
Journal:  Eur J Nucl Med       Date:  1992

2.  Evaluation of technetium 99m cyclobutylpropylene amine oxime as a potential brain perfusion imaging agent for SPET.

Authors:  L Bacciottini; F Lunghi; A Pupi; C Bonino; A R Formiconi; M T De Cristofaro; A R Petti; U Meldolesi
Journal:  Eur J Nucl Med       Date:  1990

3.  Radiochemical purity of D,L-hexamethylpropylene amine oxime and analysis of urine-excreted HMPAO decomposition species.

Authors:  V Ivancević; Z Kuster; Z Mastrović; D Ivancević
Journal:  Eur J Nucl Med       Date:  1990

4.  Quantification of technetium-99m hexamethylpropylene amine oxime brain uptake in routine clinical practice using calibrated point sources as an external standard: phantom and human studies.

Authors:  A Dobbeleir; R Dierckx
Journal:  Eur J Nucl Med       Date:  1993-08

5.  A method for stabilising technetium-99m exametazime prepared from a commercial kit.

Authors:  P S Weisner; G R Bower; L A Dollimore; A M Forster; B Higley; A E Storey
Journal:  Eur J Nucl Med       Date:  1993-08

6.  Parameters influencing SPET regional brain uptake of technetium-99m hexamethylpropylene amine oxine measured by calibrated point sources as an external standard.

Authors:  R A Dierckx; A Dobbeleir; M Maes; B A Pickut; A Vervaet; P P De Deyn
Journal:  Eur J Nucl Med       Date:  1994-06

7.  Evaluation of technetium-99m exametazime stabilised with cobalt chloride as a blood flow tracer in focal cerebral ischaemia.

Authors:  G Gartshore; P Bannan; J Patterson; B Higley; J McCulloch
Journal:  Eur J Nucl Med       Date:  1994-09

8.  Formulation of a single-component kit for the preparation of technetium-99m labelled ethyl cysteinate dimer: biological and clinical evaluation.

Authors:  A Afshan; M Jehangir; M Ashraf; A Waqar; E Chiotellis
Journal:  Eur J Nucl Med       Date:  1994-09

9.  Stabilisation of high-activity 99mTc-d,l-HMPAO preparations with cobalt chloride and their biological behaviour.

Authors:  K O Mang'era; H P Vanbilloen; C W Schiepers; A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1995-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.